The 145th Annual Meeting of the Pharmaceutical Society of Japan (Fukuoka)

Organizer: Ryuji Ikeda (Dept. Pharm., Univ. Miyazaki Hosp.), Motohiko Sano (Hoshi Univ.), Tomohiro Miyake (Dept. Pharm., Ise Red Cross Hosp.), Yukiyoshi Fujita (Div. Pharm., Gunma Prefectural Cancer Center)

The Federation of Pharmaceutical Societies of Japan, established in July 2023, functions as a platform for research exchange and sharing knowledge between basic and clinical researchers, playing a crucial role in consolidating pharmaceutical expertise. It is anticipated to contribute significantly to the advancement of cancer treatment and the improvement of patients' quality of life. Many cancer patients grapple with various side effects, as well as psychological and economic challenges associated with pharmacotherapy. Clinical pharmacists thus play a crucial role in cancer care, acting as central figures in identifying and resolving issues that impact patients' lives, using their pharmaceutical expertise. In the clinical setting, pharmacists collect and analyze information, collaborating with other healthcare professionals to provide optimal drug therapy and contribute to patient satisfaction and enhanced quality of life. On the other hand, challenges arise in healthcare due to a lack of evidence, necessitating clinical pharmacists to actively contribute to the creation of new evidence. This symposium, jointly organized by the Pharmaceutical Society of Japan and the Japanese Society of Pharmaceutical Health Care and Sciences for the second time. It brings together experts such as Board certified Oncology Pharmacists and Board certified Senior Oncology Pharmacists to discuss clinical research and the generation of new evidence. The symposium is anticipated to serve as a catalyst for discussions across a broad spectrum of fields, including outcomes of clinical pharmacy services in oncology, development of prevention methods for anticancer drug-induced side effect using data science, development of personalized precision dosing for molecularly targeted cancer therapies, prospects and challenges for future clinical pharmacy research. We look forward to the symposium becoming a milestone event that paves the way for "Pioneering New Cancer Therapies".